Two drugs that cause weight loss
ONE
Belviq link
PRESS RELEASE:
"BELVIQ did not increase incidence of cardiovascular events in study of 12,000 obese and overweight patients
- Reduction in conversion to type 2 diabetes in patients without diabetes
- Improvement in multiple cardiovascular risk factors, including lipids, blood pressure, blood glucose and renal function"
I switched to Belviq 10 mg BID on 11-15-16 as the Qsymia I was taking caused an asymptomatic resting heart rate over 100/min. I was 212.4 lbs.
On 7-16-18 I 213.8 lbs.
I wrote this blog July 31, 2015
First choice?
LOCASERIN (Belviq)Why?
May be safest drug.
Young women are less of a concern than with Qsymia.
Caution with depressed patients.
There is a concern for serotonin syndrome but to my knowledge this drug does not increase serotonin levels.
Downside: Only 50% have good response.
Adding Phetermine to Belviq Link
TWO
An early halt has been called for a phase 3 randomized clinical trial investigating renal outcomes for the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin (Invokana, Janssen) in patients with type 2 diabetes and kidney disease because of achievement of prespecified efficacy criteria.
The Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation (CREDENCE) trial is evaluating the efficacy and safety of adding canagliflozin 100 mg/day versus placebo to standard of care, which includes angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs).
The study is sponsored by Janssen and is being conducted in collaboration with the George Institute for Global Health, Australia.
The decision to halt the study nearly a year sooner than planned was based on the advice of the independent data monitoring committee following a planned interim analysis. The pre-specified criteria for the primary composite endpoint — end-stage renal disease, doubling of serum creatinine, or cardiovascular death — had been achieved. No further details about outcomes were provided in the company announcement made yesterday.
No comments:
Post a Comment